Masayuki Okuno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masayuki Okuno has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Etsuro Hatano
Department of Surgery, Graduate School of Medicine Kyoto University Kyoto Japan
10 shared publications Hiroto Nishino
Department of Surgery Division of Hepato‐Biliary‐Pancreatic and Transplant Surgery Graduate School of Medicine Kyoto University Kyoto Japan
7 shared publications- Satoru Seo
Department of Surgery, Kochi Medical School, Kochi University
5 shared publications Ikuo Nakamura
Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan
4 shared publicationsSeiko Hirono
Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan
4 shared publications- Takahiro Nishio
Department of Surgery, Graduate School of Medicine Kyoto University Kyoto Japan
4 shared publications
Latest Publications
- 1 July 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (11) , 1632-1642
Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma
Purpose: This study aimed to investigate the prognostic impact of the interval between curative‐intent local treatments in patients undergoing repeated therapies for recurrent hepatocellular carcinoma after hepatectomy. Methods: The present retrospective cohort study included 890 patients who underwent hepatectomy for HCC at our hospital between 2001 and 2020. Overall survival (OS) was evaluated from the time of each curative‐intent local treatment, according to the number of treatments received and the intervals between consecutive curative‐intent treatments for intrahepatic recurrence, up to the fourth session. Results: During follow‐up, 625 patients (65.9%) developed intrahepatic recurrence. The median intervals gradually shortened to 24.9, 14.5, 12.4, and 12.8 months from hepatectomy to the first curative treatment, from the first to the second, from the second to the third, and from the third to the fourth treatments, respectively. For the first and second curative treatments, the pretreatment interval was not an independent predictor of OS. At the third curative treatment, an interval < 18.6 months between the second and third curative treatments independently predicted poorer OS (hazard ratio [HR] 2.280 and 95% confidence interval [CI] 1.046–4.967). For the fourth curative treatment, an interval < 14.1 months between the third and fourth treatments was an independent adverse prognostic factor (HR 4.961, 95% CI 1.607–15.319). The prognostic impact of treatment interval was more pronounced in patients who underwent ≥ 3 treatments, with a significant interaction compared with < 3 treatments. Conclusions: Among patients who remained eligible for repeated curative‐intent local treatment, a shortened interval between treatments in late‐phase recurrence was an independent predictor of poor prognosis.
- 1 July 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (11) , 1632-1642
Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma
Purpose: This study aimed to investigate the prognostic impact of the interval between curative‐intent local treatments in patients undergoing repeated therapies for recurrent hepatocellular carcinoma after hepatectomy. Methods: The present retrospective cohort study included 890 patients who underwent hepatectomy for HCC at our hospital between 2001 and 2020. Overall survival (OS) was evaluated from the time of each curative‐intent local treatment, according to the number of treatments received and the intervals between consecutive curative‐intent treatments for intrahepatic recurrence, up to the fourth session. Results: During follow‐up, 625 patients (65.9%) developed intrahepatic recurrence. The median intervals gradually shortened to 24.9, 14.5, 12.4, and 12.8 months from hepatectomy to the first curative treatment, from the first to the second, from the second to the third, and from the third to the fourth treatments, respectively. For the first and second curative treatments, the pretreatment interval was not an independent predictor of OS. At the third curative treatment, an interval < 18.6 months between the second and third curative treatments independently predicted poorer OS (hazard ratio [HR] 2.280 and 95% confidence interval [CI] 1.046–4.967). For the fourth curative treatment, an interval < 14.1 months between the third and fourth treatments was an independent adverse prognostic factor (HR 4.961, 95% CI 1.607–15.319). The prognostic impact of treatment interval was more pronounced in patients who underwent ≥ 3 treatments, with a significant interaction compared with < 3 treatments. Conclusions: Among patients who remained eligible for repeated curative‐intent local treatment, a shortened interval between treatments in late‐phase recurrence was an independent predictor of poor prognosis.
- Open Access
- 26 June 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (9) , 111977
Vessel co-option negatively affects survival in patients with advanced hepatocellular carcinoma
- 26 June 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (9) , 111977
Open AccessVessel co-option negatively affects survival in patients with advanced hepatocellular carcinoma
- Open Access
- 31 March 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (4)
Spatial and functional polarization of cancer-associated fibroblasts with CXCR4-mediated immune modulation in hepatocellular carcinoma
Background: Cancer-associated fibroblasts (CAFs) represent a predominant cell population in the tumor microenvironment (TME) of hepatocellular carcinoma (HCC). How the spatial distribution of CAF subtypes relates to immune modulation within the TME remains incompletely understood. This study aimed to characterize the spatial organization of CAF subtypes in HCC and to explore their potential associations with immune contexture. Methods: Spatial transcriptomic analysis was performed on 6 HCC cases to identify CAF-enriched clusters and their spatial localization. Immunohistochemical analyses were conducted on 132 HCC sections to examine the relationship between CAF-related features, immune cell distribution, and clinical outcomes. Results: Spatial transcriptomic analysis identified distinct CAF sub-clusters, including myofibroblastic CAFs (myCAFs), which were predominantly localized within tumor regions and enriched for extracellular matrix–related gene expression; inflammatory CAFs (iCAFs), which were preferentially localized within tumor septa and associated with inflammatory signaling; and antigen-presenting CAFs (apCAFs), which were enriched in the peritumoral zone and exhibited gene expression patterns suggestive of immune-related functions. Interactome analysis suggested that apCAFs in the peritumoral region showed transcriptional patterns consistent with CXCL12–CXCR4–related interactions with CD8 + T cells accumulating at the tumor periphery. The enrichment of apCAFs on the outer side of tumor septa was associated with reduced intra-tumoral CD8 + T-cell infiltration and poorer prognosis, suggesting a link between apCAF distribution and an immune-excluded TME. Conclusions: Spatial transcriptomic profiling suggests that CAFs exhibit functional and spatial polarization in the TME of HCC. ApCAFs are associated with CXCR4-related immune exclusion at the tumor–stroma interface and may represent a stromal component relevant to immune modulation. These findings provide a framework for CAF–immune interactions and serve as a basis for future functional studies targeting the CXCL12–CXCR4 axis.
- 31 March 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (4)
Open AccessSpatial and functional polarization of cancer-associated fibroblasts with CXCR4-mediated immune modulation in hepatocellular carcinoma
Background: Cancer-associated fibroblasts (CAFs) represent a predominant cell population in the tumor microenvironment (TME) of hepatocellular carcinoma (HCC). How the spatial distribution of CAF subtypes relates to immune modulation within the TME remains incompletely understood. This study aimed to characterize the spatial organization of CAF subtypes in HCC and to explore their potential associations with immune contexture. Methods: Spatial transcriptomic analysis was performed on 6 HCC cases to identify CAF-enriched clusters and their spatial localization. Immunohistochemical analyses were conducted on 132 HCC sections to examine the relationship between CAF-related features, immune cell distribution, and clinical outcomes. Results: Spatial transcriptomic analysis identified distinct CAF sub-clusters, including myofibroblastic CAFs (myCAFs), which were predominantly localized within tumor regions and enriched for extracellular matrix–related gene expression; inflammatory CAFs (iCAFs), which were preferentially localized within tumor septa and associated with inflammatory signaling; and antigen-presenting CAFs (apCAFs), which were enriched in the peritumoral zone and exhibited gene expression patterns suggestive of immune-related functions. Interactome analysis suggested that apCAFs in the peritumoral region showed transcriptional patterns consistent with CXCL12–CXCR4–related interactions with CD8 + T cells accumulating at the tumor periphery. The enrichment of apCAFs on the outer side of tumor septa was associated with reduced intra-tumoral CD8 + T-cell infiltration and poorer prognosis, suggesting a link between apCAF distribution and an immune-excluded TME. Conclusions: Spatial transcriptomic profiling suggests that CAFs exhibit functional and spatial polarization in the TME of HCC. ApCAFs are associated with CXCR4-related immune exclusion at the tumor–stroma interface and may represent a stromal component relevant to immune modulation. These findings provide a framework for CAF–immune interactions and serve as a basis for future functional studies targeting the CXCL12–CXCR4 axis.
- Open Access
- 23 December 2025
- Published by S. Karger AG in Digestive Surgery
- Vol. 43 (1) , 23-34
Response Rate Correlates with the Conversion Rate in Patients with Advanced Hepatocellular Carcinoma Treated with Systemic or Hepatic Artery Infusion Chemotherapy: A Systematic Review
Introduction: The appropriate regimen for induction therapy with the intent of conversion therapy for advanced hepatocellular carcinoma (HCC) is unknown. This study aimed to evaluate whether the overall response rate (ORR) of chemotherapy correlates with the conversion rate. Methods: The studies of phase 2/3 trials of systemic or hepatic artery infusion chemotherapy (HAIC) for patients with advanced HCC were searched. Spearman’s correlation coefficient was calculated to measure the strength of the relationship between the conversion rate and the ORR. Results: A total of 42 patient groups from 32 trials were included in the analysis. The ORR and conversion rates in a total of 3,516 patients were 24.7% and 8.3%, respectively. The analysis of only the patient groups treated with 1st-line immune checkpoint inhibitors, tyrosine kinase inhibitors or HAIC revealed a strong correlation between the ORR and the conversion rate (ρ = 0.647, p = 0.0003). In addition, strong correlations between the ORR and median progression-free survival (PFS)/overall survival (OS) were observed (ρ = 0.772, p < 0.0001 and ρ = 0.754, p < 0.0001, respectively). Conclusion: Because of the strong correlations of the ORR with the conversion rate and PFS/OS, regimens with high ORRs may be used for patients with advanced HCC who are potential candidates for conversion therapy.
- 23 December 2025
- Published by S. Karger AG in Digestive Surgery
- Vol. 43 (1) , 23-34
Open AccessResponse Rate Correlates with the Conversion Rate in Patients with Advanced Hepatocellular Carcinoma Treated with Systemic or Hepatic Artery Infusion Chemotherapy: A Systematic Review
Introduction: The appropriate regimen for induction therapy with the intent of conversion therapy for advanced hepatocellular carcinoma (HCC) is unknown. This study aimed to evaluate whether the overall response rate (ORR) of chemotherapy correlates with the conversion rate. Methods: The studies of phase 2/3 trials of systemic or hepatic artery infusion chemotherapy (HAIC) for patients with advanced HCC were searched. Spearman’s correlation coefficient was calculated to measure the strength of the relationship between the conversion rate and the ORR. Results: A total of 42 patient groups from 32 trials were included in the analysis. The ORR and conversion rates in a total of 3,516 patients were 24.7% and 8.3%, respectively. The analysis of only the patient groups treated with 1st-line immune checkpoint inhibitors, tyrosine kinase inhibitors or HAIC revealed a strong correlation between the ORR and the conversion rate (ρ = 0.647, p = 0.0003). In addition, strong correlations between the ORR and median progression-free survival (PFS)/overall survival (OS) were observed (ρ = 0.772, p < 0.0001 and ρ = 0.754, p < 0.0001, respectively). Conclusion: Because of the strong correlations of the ORR with the conversion rate and PFS/OS, regimens with high ORRs may be used for patients with advanced HCC who are potential candidates for conversion therapy.
- Open Access
- 29 November 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 794, 153071
Activated hepatic stellate cells are required for Hippo–YAP activation and functional liver regeneration following portal vein ligation in mice
- 29 November 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 794, 153071
Open AccessActivated hepatic stellate cells are required for Hippo–YAP activation and functional liver regeneration following portal vein ligation in mice
- Open Access
- 8 July 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (6) , 1369-1370
Clarifying Treatment Compliance and Future Directions in Perioperative Chemotherapy for Resectable Colorectal Liver Metastases
- 8 July 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (6) , 1369-1370
Open AccessClarifying Treatment Compliance and Future Directions in Perioperative Chemotherapy for Resectable Colorectal Liver Metastases
- Open Access
- 27 September 2024
- Published by Wiley in Hepatology Research
- Vol. 55 (1) , 94-105
A classification model for resectability in hepatocellular carcinoma patients
Aim: Some patients undergoing liver resection for hepatocellular carcinoma (HCC) have poor outcomes. Therefore, we aimed to propose a new resectability classification for patients with HCC.Methods: We classified patients into three categories: resectable (R), borderline resectable (BR), and unresectable (UR). Patients (n = 409) who underwent hepatectomy for HCC were assigned to the non‐UR (R and BR classes combined; n = 285) and UR‐HCC classes (n = 68; training cohort). Patient characteristics in the BR‐HCC and R‐HCC groups were compared. The new criteria were tested in a validation cohort (n = 295).Results: Of the 285 patients, 229 and 56 were classified into the R‐ and BR‐HCC classes, respectively, using macrovascular invasion, tumor size, and future liver remnant/modified albumin‐bilirubin scores. Patients with BR‐HCC demonstrated significantly worse progression‐free and overall survival (p < 0.0001 and p < 0.0001, respectively) than patients with R‐HCC in the training cohort. Similar results were observed in the validation cohort. Multivariate analysis of the non‐UR‐HCC group in the training cohort revealed that the tumor number and BR‐HCC were independent predictive factors for poor overall survival.Conclusions: This classification can help select patients with BR‐HCC for preoperative treatment before considering surgery.
- 27 September 2024
- Published by Wiley in Hepatology Research
- Vol. 55 (1) , 94-105
Open AccessA classification model for resectability in hepatocellular carcinoma patients
Aim: Some patients undergoing liver resection for hepatocellular carcinoma (HCC) have poor outcomes. Therefore, we aimed to propose a new resectability classification for patients with HCC.Methods: We classified patients into three categories: resectable (R), borderline resectable (BR), and unresectable (UR). Patients (n = 409) who underwent hepatectomy for HCC were assigned to the non‐UR (R and BR classes combined; n = 285) and UR‐HCC classes (n = 68; training cohort). Patient characteristics in the BR‐HCC and R‐HCC groups were compared. The new criteria were tested in a validation cohort (n = 295).Results: Of the 285 patients, 229 and 56 were classified into the R‐ and BR‐HCC classes, respectively, using macrovascular invasion, tumor size, and future liver remnant/modified albumin‐bilirubin scores. Patients with BR‐HCC demonstrated significantly worse progression‐free and overall survival (p < 0.0001 and p < 0.0001, respectively) than patients with R‐HCC in the training cohort. Similar results were observed in the validation cohort. Multivariate analysis of the non‐UR‐HCC group in the training cohort revealed that the tumor number and BR‐HCC were independent predictive factors for poor overall survival.Conclusions: This classification can help select patients with BR‐HCC for preoperative treatment before considering surgery.
- 7 May 2024
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 13 (3) , 306-312
A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response
Here, we present a patient with hepatocellular carcinoma complicated by tumor thrombosis into the main portal trunk and perihepatic lymph node metastases who was treated with atezolizumab plus bevacizumab. Shrinkage of the main tumor, portal vein thrombosis, and lymph node metastases were achieved; therefore, hepatectomy with lymphadenectomy could be performed. Final pathology indicated a complete pathological response in the main tumor, portal vein thrombosis, and perihepatic lymph nodes. The patient is currently alive with no evidence of recurrence on radiological assessment at 3 months after surgery.
- 7 May 2024
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 13 (3) , 306-312
A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response
Here, we present a patient with hepatocellular carcinoma complicated by tumor thrombosis into the main portal trunk and perihepatic lymph node metastases who was treated with atezolizumab plus bevacizumab. Shrinkage of the main tumor, portal vein thrombosis, and lymph node metastases were achieved; therefore, hepatectomy with lymphadenectomy could be performed. Final pathology indicated a complete pathological response in the main tumor, portal vein thrombosis, and perihepatic lymph nodes. The patient is currently alive with no evidence of recurrence on radiological assessment at 3 months after surgery.
- Open Access
- 30 October 2023
- Published by Springer Nature in Research Square
Surgical intervention after lenvatinib treatment in patients with advanced hepatocellular carcinoma
Background Survival efficacy and prognostic factors in patients with advanced hepatocellular carcinoma (HCC) who underwent surgical intervention after lenvatinib treatment is not well-understood.Methods Patients with advanced HCC who had lenvatinib treatment were retrospectively analyzed.Results Of 70 patients who were treated with lenvatinib, 14 patients underwent surgical intervention after lenvatinib treatment for 4–28 weeks. PFS was significantly longer in patients with surgical intervention than in patients with non-surgical treatment (median, 8.6 vs. 5.1 months, p = 0.019). Non-significant longer OS was also observed in patients with surgical intervention compared to patients with non-surgical treatment (median, unreached vs. 21.0 months, p = 0.206). In patients who underwent surgical intervention, 2 patients had a PR, and 12 had SD according to RECIST ver. 1.1 criteria. The serum AFP level was significantly lower after lenvatinib treatment than before lenvatinib treatment (median, 19.2 vs. 196.5 ng/mL, p = 0.0081). Eleven patients underwent curative surgery with a 14% major postoperative complication (Clavien‒Dindo ≥ IIIa) rate. Patients who exhibited decreases in AFP levels or were within the normal range of AFP levels during lenvatinib treatment had significantly longer PFS (median, 8.6 vs. 3.0 months, p = 0.0009) and OS (median, unreached vs. 12.4 months, p = 0.012) than patients who had AFP levels beyond the normal range that did not decrease during lenvatinib treatment.Conclusions Surgical intervention after lenvatinib treatment for advanced HCC was associated with longer PFS. Patients exhibiting decreases in AFP levels or were within the normal limit of AFP levels may be good candidates for surgical intervention after lenvatinib treatment for advanced HCC.
- 30 October 2023
- Published by Springer Nature in Research Square
Open AccessSurgical intervention after lenvatinib treatment in patients with advanced hepatocellular carcinoma
Background Survival efficacy and prognostic factors in patients with advanced hepatocellular carcinoma (HCC) who underwent surgical intervention after lenvatinib treatment is not well-understood.Methods Patients with advanced HCC who had lenvatinib treatment were retrospectively analyzed.Results Of 70 patients who were treated with lenvatinib, 14 patients underwent surgical intervention after lenvatinib treatment for 4–28 weeks. PFS was significantly longer in patients with surgical intervention than in patients with non-surgical treatment (median, 8.6 vs. 5.1 months, p = 0.019). Non-significant longer OS was also observed in patients with surgical intervention compared to patients with non-surgical treatment (median, unreached vs. 21.0 months, p = 0.206). In patients who underwent surgical intervention, 2 patients had a PR, and 12 had SD according to RECIST ver. 1.1 criteria. The serum AFP level was significantly lower after lenvatinib treatment than before lenvatinib treatment (median, 19.2 vs. 196.5 ng/mL, p = 0.0081). Eleven patients underwent curative surgery with a 14% major postoperative complication (Clavien‒Dindo ≥ IIIa) rate. Patients who exhibited decreases in AFP levels or were within the normal range of AFP levels during lenvatinib treatment had significantly longer PFS (median, 8.6 vs. 3.0 months, p = 0.0009) and OS (median, unreached vs. 12.4 months, p = 0.012) than patients who had AFP levels beyond the normal range that did not decrease during lenvatinib treatment.Conclusions Surgical intervention after lenvatinib treatment for advanced HCC was associated with longer PFS. Patients exhibiting decreases in AFP levels or were within the normal limit of AFP levels may be good candidates for surgical intervention after lenvatinib treatment for advanced HCC.
- 24 November 2022
- Published by Springer Nature
- p. 43-48
Advanced Techniques in Multiple Metastases: Fiduciary Markers and Completion Ablation
- 24 November 2022
- Published by Springer Nature
- p. 43-48
Advanced Techniques in Multiple Metastases: Fiduciary Markers and Completion Ablation